CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
20-896/S-010/S-011

Chemistry Review(s)

CHEMIST'S REVIEW

1. ORGANIZATION	2. NDA NUMBER
HFD-150 DODP	20-896

3. NAME AND ADDRESS OF APPLICANT:	4. AF NUMBER
Hoffmann-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110-1199	
	5. SUPPLEMENT (S) NUMBER(S) DATES(S)

6. NAME OF DRUG	7. NONPROPRIETARY NAME	SE1-010 BZ	5/15/2001
XELODA Tablets	Capecitabine		

8. SUPPLEMENT PROVIDES FOR: an efficacy supplement for the new indication and a claim for categorical exclusion from the environmental assessment requirement for the additional use of the approved drug Xeloda,	9. AMENDMENTS DATES

10. PHARMACOLOGICAL CATEGORY	11. HOW DISPENSED	12. RELATED IND/NDA/DMF
anticancer	RX ✓ OTC _	

13. DOSAGE FORM(S)	14. POTENCY	
Tablets	150 and 500mg/tablets	

15. CHEMICAL NAME AND STRUCTURE

5'-Deoxy-5-fluoro-N-[4-pentyloxycarbonyl]-cytidine



$C_{15}H_{22}FN_3O_6$, MW = 359.35

16. RECORDS AND REPORTS

CURRENT YES ✓ NO_
REVIEWED YES_ NO_

17. COMMENTS

Company submitted an amendment to efficacy supplement (S-10) for treatment of metastatic breast cancer in the combination of Xeloda (capecitabine) with Taxoterel (docetaxel)and claim for categorical exclusion from environmental assessment requirement for the additional use of Xeloda in this combination treatment. The EIC calculation qualifies for categorical exclusion.

18. CONCLUSIONS AND RECOMMENDATIONS

Approval is recommended.

19. REVIEWER

NAME	SIGNATURE	DATE COMPLETED
Chengyi Liang, Ph.D.	/S/	5/18/2001

DISTRIBUTION	NDA 20-896/BC	DIVISION FILE	Reviewer: C. Liang HFD-150	Project Manager: M. Pelosi HFD-150	Chemistry Team Leader: E. Duffy HFD-150

/S/

5/18/01

EA

Roche

Pharmaceuticals

DUPLICATE

May 14, 2001

Food and Drug Administration
Division of Oncology Drug Products, HFD-150
Office of Drug Evaluation I
Center for Drug Evaluation and Research
1451 Rockville Pike, Woodmont II Building
Rockville, MD 20852



NDA SUPP AMEND
SE7-010
B2

Re: NDA 20-896/S-010: Amendment to Efficacy Supplement
XELODA® (capecitabine) in Combination with Taxotere® (docetaxel)
in Metastatic Breast Cancer
Environmental Assessment and CMC Commitment

Ladies and Gentlemen:

Hoffmann-La Roche Inc. (sponsor of NDA 20-896) is submitting an amendment to Efficacy Supplement S-010, Xeloda® (capecitabine) in Combination with Taxotere® (docetaxel) for treatment of metastatic breast cancer. This submission contains a claim for categorical exclusion from the environmental assessment requirement for the additional use of Xeloda in this combination treatment. Calculation of the expected introduction concentration of the capecitabine active moiety into the aquatic environment is included in support of the claim for categorical exclusion.

Roche also commits to submitting the following on or before June 8, 2001:

A comparative assessment of the dissolution profiles of the two strengths of manufactured drug product used in clinical trial SO 14999, and the same strengths of currently manufactured US commercial drug product. The raw data for the assessment will be profiles (minutes or until an is reached) performed according to current US application/compendial specifications.

Please contact me at (973) 562-3519 if you require any additional information.

Sincerely,

HOFFMANN-LA ROCHE INC.

Duane L. Voss

See CMC review

Ms. Duane L. Voss
Program Director
Drug Regulatory Affairs
Telephone: (973) 562-3519
Fax: (973) 562-3700

DLV/gb
Attachments

Roche

CLAIM FOR CATEGORICAL EXCLUSION FROM THE ENVIRONMENTAL ASSESSMENT REQUIREMENT FOR XELODA® (CAPECITABINE) WITH TAXOTERE EFFICACY SUPPLEMENT FOR BREAST CANCER

NDA 20-896/S-010

XELODA® (capecitabine) TABLETS (150 mg AND 500 mg)

Hoffmann-La Roche Incorporated claims a categorical exclusion from the requirement to prepare an environmental assessment in accordance with 21 CFR 25.31(b). The proposed action, approval of an NDA, will increase the use of the active moiety, but the estimated concentration of the substance at the point of entry into the aquatic environment will be below 1 part per billion. No extraordinary circumstances exist that would significantly affect the quality of the human environment as a result of the proposed action.

Redacted 3

pages of trade secret and/or confidential commercial information